Editorial Archive
The Raven Brief: Systems-Based Insights for Western New York Patients
An editorial archive of clinical insights, white papers, and investigative health analyses on complex endocrine and metabolic function. Built for the thoughtful reader seeking an advanced understanding of their individual physiology in WNY.
The Lean Mass Problem: What the GLP-1 Conversation Is Missing
GLP-1 medications produce real, measurable weight loss — and the cardiovascular data is genuine. What the prescribing conversation has not yet caught up with is what the manufacturers' own registration trials document clearly: a substantial fraction of the weight lost is lean mass, not fat.
Lean mass governs resting metabolic rate, insulin sensitivity, functional capacity, and survival. In the patient populations these drugs are now recommended for first, its preservation is especially important. This brief examines what the trial data actually shows, why it matters clinically, and what a more complete approach to metabolic care should include.
Clinical white paper · 9 pages · 15 min readWhat This Brief Covers
- What the STEP 1, SURMOUNT-1, and SEMALEAN trials actually show about lean mass loss
- Why lean mass is not cosmetic — and what its loss means metabolically
- The bone density question and the cardiovascular paradox
- What comprehensive metabolic care should include alongside or instead of GLP-1 therapy
- A clinical decision framework for two distinct patient scenarios
The Lean Mass Problem: What the GLP-1 Conversation Is Missing
The Anatomy of Fatigue: When TSH Is Not Enough
Redefining ‘Normal’: A Guide to Advanced Lab Interpretation
Receive New Issues of The Raven Brief
New issues publish quarterly. Each brief is a standalone clinical analysis — no marketing, no supplement recommendations, no wellness clichés. Just careful thinking about complex physiology.
Quarterly Publication · No Spam
Subscribe to The Raven Brief You will be directed to a secure editorial subscription form in a new window.